Prosecution Insights
Last updated: November 20, 2026
Application No. 18/837,739

COMPOSITIONS AND METHODS FOR EXPANDING LYMPHOCYTES

Non-Final OA §103
Filed
Aug 12, 2024
Priority
Feb 16, 2022 — provisional 63/310,778 +1 more
Examiner
STAVROU, CONSTANTINA E
Art Unit
1632
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
STEMCELL Technologies Canada Inc.
OA Round
1 (Non-Final)
42%
Grant Probability
Moderate
1-2
OA Rounds
1y 7m
Est. Remaining
78%
With Interview

Examiner Intelligence

Grants 42% of resolved cases
42%
Career Allowance Rate
39 granted / 93 resolved
-18.1% vs TC avg
Strong +36% interview lift
Without
With
+36.1%
Interview Lift
resolved cases with interview
Typical timeline
3y 11m
Avg Prosecution
58 currently pending
Career history
175
Total Applications
across all art units

Statute-Specific Performance

§101
3.5%
-36.5% vs TC avg
§103
43.1%
+3.1% vs TC avg
§102
20.5%
-19.5% vs TC avg
§112
30.1%
-9.9% vs TC avg
Black line = Tech Center average estimate • Based on career data from 93 resolved cases

Office Action

§103
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Election/Restrictions Applicant’s election of Group II, claims 34-35, 38, 42-45, 49, and 51 in the reply filed on 08/27/2026 is acknowledged. Because applicant did not distinctly and specifically point out the supposed errors in the restriction requirement, the election has been treated as an election without traverse (MPEP § 818.01(a)). Claims 1, 4, 7, 11-12, 14, 19, 21, 24, 27-28, and 31 are withdrawn from further consideration pursuant to 37 CFR 1.142(b) as being drawn to a nonelected Group I, there being no allowable generic or linking claim. Election was made without traverse in the reply filed on 08/27/2026. Status of the Claims Claims 1, 4, 7, 11-12, 14, 19, 21, 24, 27-28, 31, 34-35, 38, 42-45, 49, and 51 are currently pending. Claims 1, 4, 7, 11-12, 14, 19, 21, 24, 27, 28, 31, 35, 38, 42-45, 49, and 51 are amended. Claims 1, 4, 7, 11-12, 14, 19, 21, 24, 27-28, and 31 have been withdrawn from further consideration pursuant to 37 CFR 1.142(b) as being drawn to a nonelected Invention, there being no allowable generic or linking claim. Claims 2-3, 5-6, 8-10, 13, 15-18, 20, 22-23, 25-26, 29-30, 32-33, 36-37, 39-41, 46-48, and 50 are cancelled. Claims 34-35, 38, 42-45, 49, and 51 have been considered on the merits. Claim Rejections - 35 USC § 103 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. Claims 34, 42-45, 49, and 51 are rejected under 35 U.S.C. 103 as being unpatentable over Wu et al (Virology Journal, “Soluble CD40 ligand-activated human peripheral B cells as surrogated antigen presenting cells: A preliminary approach for anti-HBV immunotherapy”, 2010), in view of Arjunaraja et al (Frontiers in Immunology, “Intrinsic Plasma Cell Differentiation Defects in B Cell Expansion with NF-κB and T Cell Anergy Patient B Cells”, 2017). Regarding claim 34, Wu teaches a method of expanding mammalian lymphocytes, in this case B cells, comprising seeding the lymphocytes into a culture environment comprising one or more ligands of CD40, in this case soluble CD40L, and one or more cytokines, in this case IL-4 (pg. 5, col. 2, para 2); and incubating the seeded lymphocytes thereof in the culture environment for more than one day (pg. 6, col. 1, last para). Regarding claim 42, Wu teaches that the ligand of CD40 is CD40L, which is a known protein (pg. 5, col. 2, para 2). Regarding claim 43, Wu teaches that the cytokine is IL-4 (pg. 5, col. 2, para 2). Regarding claim 45, Wu teaches that the method of culture is done with only the B cells of the method and teaches by omission that the seeding and incubating steps do not contain feeder cells, which amounts to a “feeder-free condition” of claim 45 (pg. 5, col. 2, para 2). Regarding claim 49, Wu teaches that the B cells are activated in the culture environment (see pg. 5, col. 2, para 2; “Activation of B cells by sCD40L”). Regarding claim 51, Wu teaches that the lymphocytes are seeded at a clonal density (pg. 5, col. 2, para 2). Wu does not teach that the method includes culturing the lymphocytes with a mixture of lipids as required by claim 34. Wu does not teach that the lipid mixture is chemically defined as required by claim 44. However, Arjunaraja teaches a method of activating human naïve B cells including seeding B cells in a culture environment and subjecting them to activation using anti-CD40 antibody, IL-21, and IL-2 (pg. 2, col. 2, last para spanning pg. 3). Regarding claim 34, Arjunaraja teaches supplementing the cell culture which is being activated with anti-CD40 antibody, IL-21, and IL-2 with additional IL-6, IFN-a, IL-21, and Lipid Mixture 1 (chemically defined) to generate long lived plasma cells (a subset of B cells)(pg. 2, col. 2, last para spanning pg. 3). Regarding claim 44, Arjunaraja explicitly teaches that the Lipid Mixture 1 is chemically defined (pg. 2, col. 2, last para spanning pg. 3). One of ordinary skill in the art would find it obvious at the effective filling date of the instant invention to combine the method of expanding B cells taught by Wu with employing a lipid mixture in culturing B cells taught by Arjunaraja to arrive at the instant invention. One of ordinary skill in the art would be motivated to make this combination because, Arjunaraja teaches supplementing the cell culture which is being activated with anti-CD40 antibody, IL-21, and IL-2 with additional IL-6, IFN-a, IL-21, and Lipid Mixture 1 (chemically defined) to generate long lived plasma cells (a subset of B cells)(pg. 2, col. 2, last para spanning pg. 3). One of ordinary skill in the art would have a reasonable expectation of success when combining Wu with Arjunaraja because both Wu and Arjunaraja and Wu teach that the method of culturing the B cells includes cytokine and CD40 activation. Therefore, the invention as a whole was prima facie obvious to one of ordinary skill in the art at the effective time of filing of the invention, especially in the absence of evidence to the contrary. Claims 35 and 38 are rejected under 35 U.S.C. 103 as being unpatentable over Wu et al (Virology Journal, “Soluble CD40 ligand-activated human peripheral B cells as surrogated antigen presenting cells: A preliminary approach for anti-HBV immunotherapy”, 2010), in view of Arjunaraja et al (Frontiers in Immunology, “Intrinsic Plasma Cell Differentiation Defects in B Cell Expansion with NF-κB and T Cell Anergy Patient B Cells”, 2017), as applied to claims 34, 42-45, 49, and 51, and in further view of De La Fuente et al (Leukemia, “Fibronectin interaction with 4 1 integrin prevents apoptosis in B cell chronic lymphocytic leukemia: correlation with Bcl-2 and Bax”, 1999). Regarding claims 35 and 38, the limitations of the independent claim 34 are taught above. Wu and Arjunaraja do not teach that the method further comprises a first type of an extracellular matrix protein in the culture environment, a first and second type of ECM protein, or a first, second, and third type of ECM protein as required by claim 35. Wu and Arjunaraja do not teach that the extracellular matrix protein is one or more from collagen, ECM1, E-cadherin, a laminin, an osteopontin, a fibronectin, a vitronectin, or a SPARC as required by claim 38. However, De La Feunte teaches the culture of a subset of B cells on fibronectin. De La Feunte teaches that B cells grown on fibronectin exhibited an anti-apoptotic effect (abstract). Regarding claim 35, De La Feunte teaches culturing B cells on fibronectin (abstract). Regarding claim 38, De La Feunte teaches that the extracellular matrix protein is fibronectin (abstract). One of ordinary skill in the art would find it obvious at the effective filling date of the instant invention to combine the method of expanding B cells taught by Wu and Arjunaraja with culturing B cells on fibronectin taught by De La Feunte to arrive at the instant invention. One of ordinary skill in the art would be motivated to make this combination because De La Feunte teaches that B cells grown on fibronectin exhibited an anti-apoptotic effect (abstract). One of ordinary skill in the art would have a reasonable expectation of success when combining Wu and Arjunaraja with De La Fuente because both Wu and Arjunaraja and Wu teach that the method of culturing the B cells includes cytokine and CD40 activation and De La Fuente teaches that fibronectin culture exhibits an anti-apoptotic effect. Therefore, the invention as a whole was prima facie obvious to one of ordinary skill in the art at the effective time of filing of the invention, especially in the absence of evidence to the contrary. Conclusion No claims are allowed. Examiner Contact Information Any inquiry concerning this communication or earlier communications from the examiner should be directed to CONSTANTINA E STAVROU whose telephone number is (571)272-9899. The examiner can normally be reached M-F 8:00-5:00. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Peter Paras can be reached at 571-272-4517. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. CONSTANTINA E. STAVROU Examiner Art Unit 1632 /TITILAYO MOLOYE/Primary Examiner, Art Unit 1632
Read full office action

Prosecution Timeline

Aug 12, 2024
Application Filed
Nov 04, 2026
Non-Final Rejection mailed — §103 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12766167
COMPOSITIONS AND METHODS OF TREATMENT OF VISION LOSS THROUGH GENERATION OF ROD PHOTORECEPTORS FROM MÜLLER GLIAL CELLS
6y 0m to grant Granted Oct 20, 2026
Patent 12760083
CHIMERIC RECEPTOR THERAPY
4y 9m to grant Granted Oct 13, 2026
Patent 12747423
CELL CULTURE MEDIUM FOR CULTURING EXTRACELLULAR VESICLES AT HIGH CONCENTRATION AND METHOD FOR PREPARING CONDITIONED MEDIUM CONTAINING HIGH CONCENTRATION OF EXTRACELLULAR VESICLES USING CELL CULTURE MEDIUM
5y 8m to grant Granted Sep 29, 2026
Patent 12716058
METHODS FOR DIRECTED DIFFERENTIATION OF PLURIPOTENT STEM CELLS TO HLA HOMOZYGOUS IMMUNE CELLS
7y 4m to grant Granted Aug 25, 2026
Patent 12678463
ACTIVATED MESENCHYMAL STEM CELLS FOR TREATING LIMB ISCHEMIA
4y 4m to grant Granted Jul 14, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
42%
Grant Probability
78%
With Interview (+36.1%)
3y 11m (~1y 7m remaining)
Median Time to Grant
Low
PTA Risk
Based on 93 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month